Sheila A Doggrell1. 1. Queensland University of Technology, School of Life Sciences, Faculty of Science and Technology, GPO Box 2434, QLD4001, Brisbane, Australia. sheila.doggrell@qut.edu.au
Abstract
BACKGROUND: The hedgehog signalling pathway is vital in early development, but then becomes dormant, except in some cancer tumours. Hedgehog inhibitors are being developed for potential use in cancer. OBJECTIVES/ METHODS: The objective of this evaluation is to review the initial clinical studies of the hedgehog inhibitor, GDC-0449, in subjects with cancer. RESULTS: Phase I trials have shown that GDC-0449 has benefits in subjects with metastatic or locally advanced basal-cell carcinoma and in one subject with medulloblastoma. GDC-0449 was well tolerated. CONCLUSIONS: Long-term efficacy and safety studies of GDC-0449 in these conditions and other solid cancers are now underway. These clinical trials with GDC-0449, and trials with other hedgehog inhibitors, will reveal whether it is beneficial and safe to inhibit the hedgehog pathway in a wide range of solid tumours or not.
BACKGROUND: The hedgehog signalling pathway is vital in early development, but then becomes dormant, except in some cancer tumours. Hedgehog inhibitors are being developed for potential use in cancer. OBJECTIVES/ METHODS: The objective of this evaluation is to review the initial clinical studies of the hedgehog inhibitor, GDC-0449, in subjects with cancer. RESULTS: Phase I trials have shown that GDC-0449 has benefits in subjects with metastatic or locally advanced basal-cell carcinoma and in one subject with medulloblastoma. GDC-0449 was well tolerated. CONCLUSIONS: Long-term efficacy and safety studies of GDC-0449 in these conditions and other solid cancers are now underway. These clinical trials with GDC-0449, and trials with other hedgehog inhibitors, will reveal whether it is beneficial and safe to inhibit the hedgehog pathway in a wide range of solid tumours or not.
Authors: Fei Tian; Josef Mysliwietz; Joachim Ellwart; Fernando Gamarra; Rudolf Maria Huber; Albrecht Bergner Journal: Clin Exp Med Date: 2011-04-26 Impact factor: 3.984
Authors: Michael J Munchhof; Qifang Li; Andrei Shavnya; Gary V Borzillo; Tracey L Boyden; Christopher S Jones; Susan D LaGreca; Luis Martinez-Alsina; Nandini Patel; Kathleen Pelletier; Larry A Reiter; Michael D Robbins; George T Tkalcevic Journal: ACS Med Chem Lett Date: 2011-12-21 Impact factor: 4.345
Authors: David W Ellison; James Dalton; Mehmet Kocak; Sarah Leigh Nicholson; Charles Fraga; Geoff Neale; Anna M Kenney; Dan J Brat; Arie Perry; William H Yong; Roger E Taylor; Simon Bailey; Steven C Clifford; Richard J Gilbertson Journal: Acta Neuropathol Date: 2011-01-26 Impact factor: 17.088